Main Text {#S2}
=========

We first replicated the finding that *Atg5* is critical in myeloid-derived cells for resistance to *Mtb* by infecting *Atg5^fl/fl^-LysM-Cre* mice^[@R4],[@R9]^. LysM-promoter-driven expression of Cre recombinase (*LysM-Cre*) results in deletion of a floxed gene in alveolar MΦ, recruited MΦ, inflammatory monocytes, monocyte-derived DC, and PMN^[@R19],[@R20]^. Following aerosol inoculation of *Mtb* into wild-type C57Bl/6 mice, bacteria replicate in innate immune cells until IFN-γ producing T cells are recruited to the lungs between 18 -- 20 days post infection (dpi), resulting in control of bacterial burden and survival^[@R21]^. Consistent with previous publications^[@R4],[@R9]^, *Atg5^fl/fl^-LysM-Cre* mice lost 23% of their weight by 20 dpi and succumbed to *Mtb* between 30 -- 40 dpi ([Fig. 1a, b](#F1){ref-type="fig"}). In contrast, *Atg5^fl/fl^* control mice showed no signs of sickness or weight loss. Bacterial titers in *Atg5^fl/fl^-LysM-Cre* mice were significantly higher at 3 weeks post infection (wpi) than those in *Atg5^fl/fl^* mice ([Fig. 1c, d](#F1){ref-type="fig"}). By 5 wpi, *Atg5^fl/fl^* mice had controlled pulmonary burden while *Atg5^fl/fl^-LysM-Cre* mice rapidly succumbed to infection ([Fig. 1b, c](#F1){ref-type="fig"}).

In cultured cells, *Atg5*, *p62/*SQSTM1, and *Ulk1* have similar roles in controlling *Mtb* survival and replication^[@R1],[@R4],[@R5],[@R22]^. We therefore explored the role of these and other genes involved in autophagy *in vivo*, by infecting mice with germline deletions of *Ulk1*, *Ulk2* (autophagy induction), *Atg4B* (isolation membrane elongation), or *p62*/SQSTM1 (substrate targeting to autophagosome). Surprisingly, mice lacking *Ulk1, Ulk2, Atg4B* or *p62* showed no signs of sickness during infection, efficiently controlled bacterial burden, and survived over 80 days with *Mtb* ([Fig. 1e--h](#F1){ref-type="fig"}, and [Extended Data Fig. 1a](#F5){ref-type="fig"}). Potential redundancy may explain the lack of a phenotype in *Ulk1*^−/−^, *Ulk2*^−/−^, *Atg4B*^−/−^, and *p62*^−/−^ mice during *Mtb* infection. However, loss of either *Ulk1* or *Ulk2* results in clear autophagy defects in cultured cells^[@R23]^, and *Atg4B*^−/−^ mice have dramatic autophagy defects in many tissues, including a nearly complete loss of LC3-II formation in the lungs, kidney and liver^[@R24]^. Regardless of issues with redundancy, these data indicate a lack of correlation between *in vitro* and *in vivo* findings of the roles of these genes in controlling *Mtb* replication.

We next tested the role of essential ATG genes other than *Atg5* in resistance to *Mtb*. If ATG5 is required *in vivo* due to its role in canonical autophagy, then *LysM-Cre* deletion of other essential autophagy genes would result in a similar phenotype as observed in *Atg5^fl/fl^-LysM-Cre* mice. Contrary to expectation, *Atg14L^fl/fl^-LysM-Cre*, *Atg12^fl/fl^-LysM-Cre*, *Atg16L1^fl/fl^-LysM-Cre*, *Atg7^fl/fl^-LysM-Cre* and *Atg3^fl/fl^-LysM-Cre* mice did not show any signs of sickness or weight loss following infection with *Mtb* and all survived over 80 dpi ([Fig. 1i](#F1){ref-type="fig"} and [Extended Data Fig. 1b](#F5){ref-type="fig"}). In addition, these mice were all able to control *Mtb* burden in a manner similar to C57Bl/6 mice ([Fig. 1j, k](#F1){ref-type="fig"}). These findings were particularly notable as these same *Atg16L1^fl/fl^-LysM-Cre*, *Atg7^fl/fl^-LysM-Cre* and *Atg3^fl/fl^-LysM-Cre* mice are dramatically more susceptible to *Toxoplasma gondii*, another pathogen for which IFN-γ plays a key role in resistance to infection^[@R12],[@R14]^. Nevertheless, to compare the relative efficacy of conditional deletion of each essential autophagy factor, LC3 lipidation and p62 degradation were measured *ex vivo* in peritoneal exudate MΦ ([Fig. 1l](#F1){ref-type="fig"}) and bronchoalveolar lavage MΦ ([Extended Data Fig. 2](#F6){ref-type="fig"}). Consistent with previous publications utilizing these mouse strains^[@R12],[@R14]^, the floxed alleles in *Atg5^fl/fl^-LysM-Cre*, *Atg16L1^fl/fl^-LysM-Cre, Atg7^fl/fl^-LysM-Cre* and *Atg3^fl/fl^-LysM-Cre* mice were effectively targeted *in vivo* resulting in similar increases in the amounts of LC3-I and p62, which indicate a defect in autophagy. Peritoneal MΦ and bronchoalveolar MΦ from *Atg14L^fl/fl^-LysM-Cre* mice also accumulated p62 while, consistent with previous findings, the levels of LC3 were largely unaffected^[@R12]^.

At 3 wpi, *Atg5^fl/fl^* mice have higher bacterial titers as compared to C57Bl/6 mice ([Fig. 1d, k](#F1){ref-type="fig"}), which we attribute to hypomorphic expression of *Atg5* from the *Atg5^fl/fl^* allele ([Extended Data Fig. 3](#F7){ref-type="fig"} and ^[@R25]^). To determine if germline hypomorphism for an essential ATG factor other than ATG5 interferes with control of *Mtb*, we infected mice that are hypomorphic for ATG16L1 (*Atg16L1^HM1^*)^[@R26]^ ([Fig. 1m](#F1){ref-type="fig"}). *Atg16L1^HM1^* mice showed no signs of sickness or weight loss following *Mtb* infection and controlled *Mtb* burden in a manner similar to C57Bl/6 mice ([Fig. 1n--p](#F1){ref-type="fig"}, [Extended Data Fig. 1c](#F5){ref-type="fig"}). Together, these data demonstrate that the loss of genes essential for canonical autophagy in LysM^+^ cells does not correlate with susceptibility to *Mtb* and suggest that ATG5 participates in a unique function not served by other essential ATG proteins. While autophagy-independent functions of ATG5 have been described^[@R12]--[@R18]^, this is the first example of ATG5 being important for a response to an infection independent of ATG16L1 and ATG12.

To further explore how ATG5 functions during *Mtb* infection, we next investigated the reports that *Atg5^fl/fl^-LysM-Cre* mice develop more severe inflammation following *Mtb* infection^[@R4],[@R9]^. Various studies have demonstrated that myeloid-specific defects in components of the membrane elongation complex (ATG5, ATG7 or ATG16L1) can cause increased inflammation *in vivo*^[@R27]--[@R29]^. To distinguish between ATG16L1-dependent versus independent roles for ATG5 in regulating inflammation we measured immune responses to *Mtb* in the lungs of *Atg5^fl/fl^-LysM-Cre*, *Atg16L1^fl/fl^-LysM-Cre* and control mice. Phenotypes specific to loss of *Atg5* might be responsible for susceptibility to *Mtb* since *Atg16L1^fl/fl^-LysM-Cre* mice control *Mtb* infection similarly to wild-type C57Bl/6 mice ([Fig. 1](#F1){ref-type="fig"}). At 2 wpi, *Atg5^fl/fl^-LysM-Cre* lungs contained larger lesions than those in C57Bl/6, *Atg5^fl/fl^, Atg16L1^fl/fl^-LysM-Cre* and *Atg16L1^fl/fl^* mice ([Fig. 2a](#F2){ref-type="fig"}), even though bacterial burdens were similar in each strain at this timepoint ([Extended Data Fig. 4](#F8){ref-type="fig"}). By 3 wpi, *Atg5^fl/fl^-LysM-Cre* lungs were severely inflamed with large lesions and extensive consolidation, while *Atg5^fl/fl^* and *Atg16L1^fl/fl^-LysM-Cre* lungs showed only moderate increases in inflammation ([Fig. 2a](#F2){ref-type="fig"}). Consistent with this, the lungs of *Atg5^fl/fl^-LysM-Cre* mice at 3 wpi contained higher levels of proinflammatory cytokines than *Atg16L1^fl/fl^-LysM-Cre* or control mice ([Fig. 2b](#F2){ref-type="fig"}). At this timepoint, the only cytokine that was significantly higher in the lungs of *Atg16L1^fl/fl^-LysM-Cre* mice compared to controls was IL-1β, however this was still only half as much IL-1β as detected in *Atg5^fl/fl^-LysM-Cre* lungs. The increased levels of IL-1β in mice lacking *Atg16L1* is consistent with previous reports showing that autophagy in MΦ negatively regulates inflammasome-dependent IL-1β production^[@R9],[@R27]--[@R29]^. The observed differences in cytokine production were a specific and active response to *Mtb* infection, as cytokine levels were not significantly different or were below the limit of detection in uninfected lungs ([Extended Data Fig. 5](#F9){ref-type="fig"}).

To characterize cell populations contributing to the inflammation, flow cytometry was performed at 2 and 3 wpi in *Atg5^fl/fl^-LysM-Cre*, *Atg16L1^fl/fl^-LysM-Cre*, and control mice. At 2 wpi, *Atg5^fl/fl^-LysM-Cre* lungs contained a significantly greater frequency of PMN than *Atg5^fl/fl^* or C57Bl/6 mice ([Fig. 2c](#F2){ref-type="fig"}, [Extended Data Fig. 6](#F10){ref-type="fig"}). This difference was more pronounced at 3 wpi, and at this time point the frequency of PMN in *Atg5^fl/fl^-LysM-Cre* lungs was also significantly higher than in *Atg16L1^fl/fl^-LysM-Cre* lungs ([Fig. 2d](#F2){ref-type="fig"}). *Atg5^fl/fl^-LysM-Cre* lungs also contained a greater percentage of inflammatory monocytes than C57Bl/6 mice at 2 wpi, however this level was similar to *Atg5^fl/fl^* lungs and, by 3 wpi, was not significantly different from any other strain. The increased inflammation in *Atg5^fl/fl^-LysM-Cre* lungs likely contributes to the severe lung pathology and morbidity observed in these mice ([Fig. 1a, b](#F1){ref-type="fig"} and [Fig. 2a--d](#F2){ref-type="fig"}). In addition, the absence of higher bacterial burden at 2 wpi ([Extended Data Fig. 4](#F8){ref-type="fig"}) indicates that the increased inflammation in the *Mtb* infected *Atg5^fl/fl^-LysM-Cre* mice is a direct result of loss of *Atg5* rather than a response to uncontrolled bacterial replication.

Excessive PMN recruitment is a hallmark of acute susceptibility to *Mtb* and is associated with uncontrolled tissue damage and progression of disease^[@R11]^. We hypothesized that the susceptibility of the *Atg5^fl/fl^-LysM-Cre* mice is related to the increased frequency of PMN in these mice during *Mtb* infection and, therefore, sought to determine if depletion of PMN would improve control of *Mtb*^[@R11]^. Antibody-mediated depletion of PMN (anti-Ly6G, clone 1A8) from 10 -- 28 dpi allowed *Atg5^fl/fl^-LysM-Cre* mice to recover their loss in weight and survive over 80 dpi ([Fig. 3a, b](#F3){ref-type="fig"}). To survive 80 dpi, PMN-depleted *Atg5^fl/fl^-LysM-Cre* mice must have functional IFN-γ signaling and T cell responses, since *Rag*^−/−^ and PMN-depleted *IFNGR*^−/−^ mice both succumb to *Mtb* by 60 dpi^[@R11]^. Furthermore, at 3 wpi, PMN-depleted *Atg5^fl/fl^-LysM-Cre* mice had significantly lower levels of proinflammatory cytokines, pulmonary burden, and lung pathology than IgG control-treated mice ([Fig. 3c--e](#F3){ref-type="fig"}). The depletion of PMN alleviated all phenotypes observed at 3 wpi in *Atg5^fl/fl^-LysM-Cre* mice, indicating that a dysfunctional PMN response leads to the susceptibility of these mice.

We next sought to determine in which cell type(s) *Atg5* is required to control *Mtb. LysM-Cre* deletion occurs in PMN, MΦ, inflammatory monocytes and myeloid-derived DC^[@R19],[@R20]^, indicating that *Atg5* plays a critical role in one or more of these populations during *Mtb* infection. Alveolar MΦ are the first cells infected upon inhalation of *Mtb* and are required for the establishment of infection^[@R30]^. Furthermore, previous *in vitro* studies suggested that a predominant role for ATG5 during *Mtb* infection is to control bacterial replication in MΦ^[@R1]--[@R4],[@R6]--[@R8]^. Therefore, we investigated whether ATG5 is required in alveolar MΦ to control *Mtb* by infecting *Atg5^fl/fl^-CD11c-Cre* mice, which lack ATG5 in alveolar MΦ and DC^[@R20]^. In contrast to *Atg5^fl/fl^-LysM-Cre* mice, *Atg5^fl/fl^-CD11c-Cre* mice did not lose weight during *Mtb* infection, were able to control bacterial burden, and survived over 80 dpi ([Fig. 4a--c](#F4){ref-type="fig"}). Alveolar MΦ from *Atg5^fl/fl^-CD11c-Cre* and *Atg5^fl/fl^-LysM-Cre* mice displayed similar autophagy defects ([Fig. 4d](#F4){ref-type="fig"} and [Extended Data Fig. 2](#F6){ref-type="fig"}), indicating that resistance to *Mtb* is neither dependent on nor correlated with autophagic capacity in alveolar MΦ. Furthermore, this suggests ATG5 plays an essential role within other cells targeted by *LysM-Cre*-mediated gene deletion, such as PMNs, recruited MΦ and/or inflammatory monocytes, to control *Mtb* infection.

We have shown that excessive PMN dominated inflammation leads to the susceptibility of *Atg5^fl/fl^-LysM-Cre* mice. To determine whether loss of *Atg5* from PMN is sufficient to cause susceptibility to *Mtb*, we next utilized *Atg5^fl/fl^-MRP8-Cre* mice, which delete *Atg5* in PMN^[@R20]^ ([Fig. 4e](#F4){ref-type="fig"}). *Atg5^fl/fl^-MRP8-Cre* mice were more susceptible to *Mtb* infection, as indicated by an average increase in weight loss compared to floxed controls ([Fig. 4f](#F4){ref-type="fig"}). However, analysis of individual mice revealed that only half of the *Atg5^fl/fl^-MRP8-Cre* mice lost weight following *Mtb* infection (between 10 -- 20% of their starting weight); the remaining 50% of mice exhibited an average 2% weight gain. This split phenotype was reproducible across multiple experiments, and was independent of differences in age, sex, or litter of the mice, suggesting a threshold effect in the susceptibility of the *Atg5^fl/fl^-MRP8-Cre* mice. To study these two distinct outcomes, we compared responses in mice that lost over 5% of their starting weight at 20 dpi ("susceptible") with the remaining mice ("healthy") ([Fig. 4g](#F4){ref-type="fig"}). At 3 wpi, lungs from susceptible *Atg5^fl/fl^-MRP8-Cre* mice exhibited higher bacterial burden, cytokine responses, and frequency of PMN ([Fig. 4h--j](#F4){ref-type="fig"}, [Extended Data Fig. 7](#F11){ref-type="fig"}). The susceptible *Atg5^fl/fl^-MRP8-Cre* mice display the same phenotypes as the *Atg5^fl/fl^-LysM-Cre* mice, demonstrating a PMN-intrinsic role for ATG5 during acute *Mtb* infection. However, the incomplete penetrance of susceptibility in *Atg5^fl/fl^-MRP8-Cre* mice suggests that the extreme sensitivity of *Atg5^fl/fl^-LysM-Cre* mice to *Mtb* results from the loss of *Atg5* in MΦ and monocytes, as well as PMN. Notably, *Atg16L1^fl/fl^-LysM-Cre* mice are not susceptible to *Mtb* infection even though PMN ([Extended Data Fig. 8](#F12){ref-type="fig"}), in addition to MΦ ([Fig. 1l](#F1){ref-type="fig"} and [Extended Data Fig. 2](#F6){ref-type="fig"}), from *Atg16L1^fl/fl^-LysM-Cre* and *Atg5^fl/fl^-LysM-Cre* mice have a similar defect in autophagy. This further supports that ATG5 functions, at least in part, independently of ATG16L1 to protect mice from *Mtb* infection.

Despite numerous *in vitro* studies emphasizing a role for autophagy in MΦ during *Mtb* infection (including, but not limited to ref ^[@R1]--[@R8]^), our data show that loss of genes essential for canonical autophagy does not correlate with susceptibility to *Mtb* in the context of a complete immune response in the host. Importantly, mice used in our studies have similar autophagy defects and have been used in prior publications to investigate the function of individual ATG factors^[@R12]--[@R15]^, validating these mice as suitable genetic models to study autophagy *in vivo*. Our studies indicate that prior reports analyzing the role of only a single autophagy gene to conclude that canonical autophagy is responsible for the phenotypes observed need to be reexamined. The observation that the *Atg5^fl/fl^* and *Atg5^fl/fl^-LysM-Cre* mice have only small differences in *Mtb* burden supports the other data presented herein that the dramatic difference in the inflammatory response is the predominant driver of susceptibility in *Atg5^fl/fl^-LysM-Cre* mice during *Mtb* infection. The apparent insignificance of macroautophagy for controlling *Mtb* replication may reflect that *Mtb* encodes highly effective inhibitors of canonical autophagy, however these mechanisms have yet to be described. Furthermore, studies investigating loss of autophagy, including this one, do not address whether activation of autophagy could enhance restriction of *Mtb* replication.

By analyzing different Cre-mediated deletion strains, we have found that loss of *Atg5* in PMN, but not alveolar MΦ or DC, can result in loss of control of *Mtb* infection*,* but the severe susceptibility of the *Atg5^fl/fl^-LysM-Cre* mice relies on deletion of *Atg5* in multiple LysM^+^ cell types. These data also reveal a PMN-intrinsic role for ATG5 during *Mtb* infection. Importantly, the reversal of all phenotypes in the *Atg5^fl/fl^-LysM-Cre* mice upon PMN-depletion positions PMN as a major driver in the dysfunctional response in these mice. Our experiments point to a model where infection with *Mtb* induces a proinflammatory response that leads to the recruitment of PMN to the lung. The absence of *Atg5* expression within the responding myeloid cells leads to uncontrolled accumulation of PMN in the lung, which causes increased pathology and likely provides an expanded niche for bacterial infection. The animal then succumbs to infection before the adaptive immune response is able to control the inflammation and bacterial replication. Together, the *in vivo* genetic analyses presented here argue for a shift in focus onto macroautophagy-independent roles of ATG5 in controlling resistance to *Mtb* infection *in vivo*.

Methods {#S3}
=======

Cells and Media {#S4}
---------------

*Mycobacterium tuberculosis* Erdman was cultured at 37 C in 7H9 (broth) or 7H10 (agar) (Difco) medium supplemented with 10% oleic acid/albumin/dextrose/catalase (OADC), 0.5% glycerol, and 0.05% Tween 80 (broth).

*Ex vivo* MΦ were enriched from mice via bronchoalveolar lavage or peritoneal lavage with DMEM + 10% FBS + 1% MEM non-essential amino acids (Cellgro 25--025-CI) + 100 U/mL Penicillin + 100 mg/mL Streptomycin (Sigma P4333). Lavage cells were treated with ACK lysis buffer (0.15M NH~4~Cl, 10mM KHCO~3~, 0.1mM EDTA) to lyse red blood cells, plated in tissue culture treated plates, and incubated at 37°C in 5% CO~2~ for at least 4 hours to allow adherence of MΦ^[@R14]^. Wells were washed vigorously with PBS to remove non-adherent cells and lysed in 2X Laemmli buffer for western blot analysis.

Bone marrow derived MΦ were isolated from femurs and tibias of mice, and cultured in DMEM + 20% FBS + 10% supernatant from 3T3 cells overexpressing M-CSF + 1% MEM non-essential amino acids (Cellgro 25--025-CI) + 100 U/mL penicillin and 100 μg/mL streptomycin (Sigma P4333) at 37° C in 5% CO~2~.

PMN for *ex vivo* western blotting analysis were purified from uninfected bone marrow by negative selection via MACS column (Miltenyi Biotech, 130-097-658) according to manufacturer's guidelines and immediately lysed in 2X Laemmi buffer.

Western Blotting {#S5}
----------------

Protein samples were diluted in 2X Laemmli buffer, resolved using 4--20% polyacrylamide gels (BioRad \#456-1096) transferred to PVDF membrane (GE Healthcare 10600023) and detected with the following antibodies: LC3b (Sigma L7543 - detects LC3-I and LC3-II), p62 / *SQSTM1* (Sigma P0067), ATG5 (Sigma A2859), β-actin (Cell Signaling Technology \#4970) and goat-anti-mouse:HRP and goat-anti-rabbit:HRP as appropriate. HRP was detected using Western Lightning Plus ECL (PerkinElmer **\#**NEL103001EA) for actin or ECL Prime (GE Healthcare RPN2232) for LC3b, p62 and ATG5. For gel source data, see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

Mouse strains {#S6}
-------------

Adult mice (age 7--15 weeks) of both sexes were used and mouse experiments were randomized. No blinding was performed during animal experiments. All mice used have been fully backcrossed to a C57Bl/6 background. Sample sizes are detailed in [Supplemental Figure 2](#SD2){ref-type="supplementary-material"} and were sufficient to detect differences as small as 10% using the statistical methods described. *Atg5^fl/fl^-LysM-Cre, Atg7^fl/fl^-LysM-Cre, Atg16L1^fl/fl^-LysM-Cre, Atg3^fl/fl^-LysM-Cre*, and *Atg14L1^fl/fl^-LysM-Cre*, and all floxed control mice have been previously described^[@R12]--[@R14]^. *Atg14L^fl/fl^-LysM-Cre* and floxed control mice were kindly provided by Dr. Shizuo Akira, Osaka University, Japan. *Atg3^fl/fl^-LysM-Cre* mice were derived from *Atg3^fl/fl^* mice kindly provided by Dr. You-Wen He, Duke University, USA^[@R31]^. *Atg12^fl/fl^-LysM-Cre* mice were derived from *Atg12^fl/fl^* mice^[@R32]^. *Atg16L1^HM1^* mice have been previously described (HM1, BC0122 strain)^[@R26]^. *p62*^−/−^ mice were kindly supplied by Dr. Eileen White at Rutgers University^[@R33]^. *Atg4B*^gt/gt^ mice were previously described, and are referred to as *Atg4B*^−/−^ throughout the text^[@R24]^. *Ulk1*^−/−^ and *Ulk2*^−/−^ mice were kindly provided by Dr. Sharon Tooze at the London Research Institute^[@R34],[@R35]^. *Atg5^fl/fl^-CD11c-Cre* and *Atg5^fl/fl^-MRP8-Cre* mice were generated in our facility by crossing *Atg5^fl/fl^* to *CD11c-Cre* (The Jackson Laboratory 007567) and *MRP8-Cre* (The Jackson Laboratory 021614).

All procedures involving animals were conducted following the National Institute of Health guidelines for housing and care of laboratory animals and performed in accordance with institutional regulations after protocol review and approval by the Institutional Animal Care and Use Committee of The Washington University in St. Louis School of Medicine (protocol \#20130156, Analysis of Mycobacterial Pathogenesis). Washington University is registered as a research facility with the United States Department of Agriculture and is fully accredited by the American Association of Accreditation of Laboratory Animal Care. The Animal Welfare Assurance is on file with OPRR-NIH. All animals used in these experiments were subjected to no or minimal discomfort. All mice were euthanized by CO~2~ asphyxiation, which is approved by The Panel on Euthanasia of the American Veterinary Association.

*Mtb* infection of mice {#S7}
-----------------------

Before infection, exponentially replicating *Mtb* were washed in PBS + 0.05% Tween-80, and sonicated to disperse clumps. 7- to 15-week-old female and male mice were exposed to 8 × 10^7^ colony forming units (CFU) of *Mtb* in an Inhalation Exposure System (Glas-Col), which delivers \~100 bacteria to the lung per animal. At 24 hours post infection, the bacterial titers in the lungs of at least two mice were determined to confirm the dose of *Mtb* inoculation. The dose determined from these mice is assumed to represent the average dose received by all mice in the same infection. Bacterial burden was determined by plating serial dilutions of lung homogenates onto 7H10 agar plates. Plates were incubated at 37°C in 5% CO~2~ for 3 weeks prior to counting colonies.

Flow cytometry {#S8}
--------------

Lungs were perfused with sterile PBS and digested at 37°C for 1 hour with 625 μg/mL collagenase D (Roche 11088875103) and 75 U/mL DNase I (Sigma D4527). Single cell suspensions stained in PBS + 2% FBS + 0.1% sodium azide in the presence of Fc receptor blocking antibody (BD Pharmingen 553541) and stained with the antibodies against the following mouse markers: CD11b_PerCP-Cy5.5 (BD Pharmingen 550993), CD11c_APC-Cy7 (eBioscience 47-0114), Ly6C_PE (BD Pharmingen 560592), Ly6G_PE-Cy7 (BD Pharmingen 560601), and F4/80_APC (Invitrogen MF48005). The FITC channel was used to determine autofluorescence. Cells were stained for 20 minutes at 4C and then fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 20 minutes at room temperature. Flow cytometry was performed on a FACSCanto II (BD Bioscience) and data was analyzed with FlowJo (Tree Star Inc.). Gating strategies are depicted in [Extended Data Fig. 6a](#F10){ref-type="fig"}.

Cytokine analysis {#S9}
-----------------

Lungs (right lobe) were homogenized in 1mL (uninfected mice) or 5mL (*Mtb*-infected mice) PBS + 0.05% Tween-80. Homogenized tissue supernatants were filtered (0.22um) and analyzed by ELISA according to manufacturer's guidelines (R&D systems): KC/CXCL1 (DY453), IFN-γ (DY485), TNF-α (DY410), IL-1α (DY400), IL-1α (DY401), IL-6 (DY406), IL-17 (DY421), MIP-1α/CCL3 (DY450), MIP-2/CXCL2 (DY452), and G-CSF (DY414).

RNA extraction and quantification {#S10}
---------------------------------

Following tissue disruption by bead-beating (MP Biosystems), RNA was extracted from *Mtb*-infected lungs using the RNeasy Kit according to manufacturer's guidelines (Qiagen 74106). cDNA was made with SuperScript III reverse transcriptase using oligo-dT primers (Life Technologies 18080-051). qRT-PCR was performed using iTAQ SYBR Green (BioRad 172-5121) and transcript levels were normalized to actin. The following primers were used: *Atg16L1-fwd* 5′-CCGAATCTGGACTGTGGATG-3′, *Atg16L1-rev* 5′CGGAGATCCCAGAGTTTGAG-3′, *Actin-fwd* 5′-ACCTTCTACAATGAGCTGCG-3′, and *Actin-rev* 5′-CTGGATGGCTACGTACATGG-3′

PMN depletion {#S11}
-------------

Mice were treated with 0.2 mg anti-Ly6G (clone 1A8) or 0.2 mg rat IgG (Sigma I8015) via i.p. injection every 48 hours between day 10 and 28 post infection. Efficacy of PMN depletion was confirmed by loss of CD11b^+^ Gr-1^high^ cells in lungs at 21 dpi. Anti-Ly6G was collected from 1A8 hybridoma^[@R36]^ grown in Serum Free Medium (Gibco \#12045-076) in CL350 Bioreactor flasks (Argos Technologies \#900 10).

Data and Statistics {#S12}
-------------------

All experiments were performed at least twice. When shown, multiple samples represent biological (not technical) replicates of mice randomly sorted into each experimental group. No blinding was performed during animal experiments. Animals were only excluded when pathology unrelated to *Mtb* infection was present (i.e. weight loss due to malocculsion). Determination of statistical differences was performed with Prism 5 (Graphpad Software, Inc) using log-rank Mantel-Cox test (survival), unpaired two-tailed t-test (to compare two groups with similar variances), or one-way ANOVA with Bonferonni's Multiple Comparison test (to compare more than two groups). Sample sizes were sufficient to detect differences as small as 10% using the statistical methods described. When used, center values and error bars represent the mean ± S.E.M. In all figures, all significant differences are indicated by asterisks: \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001, \*\*\*\* *P* \< 0.0001. Non-significant comparisons of particular interest are noted in figures by n.s. (not significant). Sample sizes and the results of all comparisons can be found in [Supplementary Figure 2](#SD2){ref-type="supplementary-material"}.

Extended Data {#S13}
=============

![Survival of mice with defects in autophagy genes other than *Atg5*\
Percent survival of mice following infection with 100 CFU of aerosolized *Mtb.* **a**, Survival of C57Bl/6 (open squares), *Ulk1*^−/−^ (blue triangles), *Ulk2*^−/−^ (inverted pink triangles), *Atg4B*^−/−^ (red diamonds), and *p62*^−/−^ (green circles) mice. **b**, Survival of *Atg14L^fl/fl^-LysM-Cre* (purple diamonds), *Atg12^fl/fl^-LysM-Cre* (red inverted triangles), *Atg16L1^fl/fl^-LysM-Cre* (green triangles), *Atg7^fl/fl^-LysM-Cre* (pink diamonds), *Atg3^fl/fl^-LysM-Cre* (brown circles) and corresponding floxed control mice. Floxed control mice are shown in open shapes, LysM-Cre-expressing mice are shown in closed shapes. **c**, Survival of C57Bl/6 (open squares), *Atg16L1^HM1^* (open circles). Samples represent biological replicates. See [Supplementary Figure 2](#SD2){ref-type="supplementary-material"} for sample sizes.](nihms738923f5){#F5}

![Analysis of autophagy in bronchoalveolar MΦ\
Western blot analysis of p62, LC3, and actin levels in *ex vivo* macrophages isolated from bronchoalveolar lavages of uninfected mice. For gel source data, see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.](nihms738923f6){#F6}

![*Atg5^fl/fl^* bone marrow derived MΦ are hypomorphic for ATG5\
Western blot analysis of ATG5 (ATG5--ATG12 conjugate, 56 kDa) and actin in uninfected bone marrow derived MΦ. For gel source data, see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.](nihms738923f7){#F7}

![Loss of *Atg5* or *Atg16L1* in LysM^+^ cells does not lead to increased CFU at 2 wpi\
Log pulmonary CFU at 2 weeks post infection (wpi). Samples represent biological replicates.](nihms738923f8){#F8}

![Cytokine levels in uninfected lungs\
Concentration of cytokines in lungs (homogenized in 1mL) from uninfected mice. Levels of IFN-γ, IL-6, MIP-1α, IL-17, and G-CSF were below the limit of detection. C57Bl/6 (grey solid bars), *Atg5^fl/fl^* (blue striped bars), *Atg5^fl/fl^-LysM-Cre* (blue solid bars), *Atg16L1^fl/fl^* (green striped bars), *Atg16L1^fl/fl^-LysM-Cre* (green solid bars). Statistical differences were determined by one-way ANOVA and Bonferonni's multiple comparison test. n.s., not significant. Samples represent biological replicates. See [Supplementary Figure 2](#SD2){ref-type="supplementary-material"} for sample sizes and results from all statistical comparisons.](nihms738923f9){#F9}

![Number of inflammatory cells in lungs of mice at 2 and 3 wpi (related to [Fig. 2](#F2){ref-type="fig"})\
**a,** Gating strategy for analysis of inflammatory cells in lungs at 2 and 3 wpi. Single lung cells were gated based on CD11b, CD11c, Ly6G, Ly6C and autofluorescence (auto). The parental gate is shown above each contour plot. Representative data is shown from an *Atg5^fl/fl^* mouse at 2 wpi. **b, c,** C57Bl/6 (grey solid bars), *Atg5^fl/fl^* (blue striped bars), *Atg5^fl/fl^-LysM-Cre* (blue solid bars), *Atg16L1^fl/fl^* (green striped bars), *Atg16L1^fl/fl^-LysM-Cre* (green solid bars). Mean number of alveolar MΦ, PMN, recruited MΦ, and inflammatory monocytes in lungs at 2 wpi (**b**) and 3 wpi (**c**). Flow cytometry data presented in (**b**) and (**c**) and in [Fig. 2](#F2){ref-type="fig"} are the compilation of results from five experiments. In some experiments, different amounts of lung were collected for analysis, making it difficult to compare the average number of each cells between strains, unless the data is normalized (as done in [Fig. 2c, d](#F2){ref-type="fig"} -- percentage of total cells). Therefore, to compare the raw number of cells detected in each cell population, each mouse analyzed at 2 wpi (**d**) and 3 wpi (**e**) has been graphed individually. Each line represents a different mouse, with dots indicating the number of total cells, alveolar MΦ, PMN, recruited MΦ and inflammatory monocytes. Statistical differences were determined by one-way ANOVA and Bonferonni's multiple comparison test (**b, c**). *\* P* \< 0.05. Notable comparisons that were not significantly different are designated as n.s. Samples represent biological replicates. See [Supplementary Figure 2](#SD2){ref-type="supplementary-material"} for sample sizes and results from all statistical comparisons.](nihms738923f10){#F10}

![Number of inflammatory cells in lungs of mice at 3 wpi (related to [Fig. 4](#F4){ref-type="fig"})\
Number of alveolar MΦ, PMN, recruited MΦ, and inflammatory monocytes in lungs at 3 wpi. C57Bl/6 (grey solid bars), *Atg5^fl/fl^* (blue striped bars), *Atg5^fl/fl^-LysM-Cre* (blue solid bars), "healthy" *Atg5^fl/fl^-MRP8-Cre* (purple striped bars), and "susceptible" *Atg5^fl/fl^-MRP8-Cre* (purple solid bars). Statistical differences were determined by one-way ANOVA and Bonferonni's multiple comparison test *\* P* \< 0.05. Notable comparisons that were not significantly different are designated as n.s. Samples represent biological replicates. See [Supplementary Figure 2](#SD2){ref-type="supplementary-material"} for sample sizes and results from all statistical comparisons.](nihms738923f11){#F11}

![Analysis of autophagy in bone marrow PMN\
Western blot analysis of p62, LC3, and actin in bone marrow PMN from uninfected mice. Each lane represents an individual mouse. Two replicates of the *Atg5^fl/fl^-LysM-Cre* and *Atg16L1^fl/fl^-LysM-Cre* mice are shown. For gel source data, see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.](nihms738923f12){#F12}
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![ATG5, in contrast to other ATG factors, is essential to control *Mtb* infection\
**a -- k**, Mice infected with approximately 100 CFU of *Mtb* were monitored at various days post infection (dpi) or weeks post infection (wpi). **a,** Weight change, **b,** survival, and **c, d,** log pulmonary CFU of *Atg5^fl/fl^* (open circles) and *Atg5^fl/fl^-LysM-Cre* (closed circles). **e, f,** Weight change, and **g, h,** log pulmonary CFU of C57Bl/6 (open squares), Ulk1^−/−^ (blue triangles), Ulk2^−/−^ (inverted pink triangles), *Atg4B*^−/−^ (red diamonds), and *p62*^−/−^ (green circles) mice. **i**, Weight change and **j, k,** log pulmonary CFU of *Atg14L^fl/fl^-LysM-Cre* (purple diamonds), *Atg12^fl/fl^-LysM-Cre* (red inverted triangles), *Atg16L1^fl/fl^-LysM-Cre* (green triangles), *Atg7^fl/fl^-LysM-Cre* (pink diamonds), *Atg3^fl/fl^-LysM-Cre* (brown circles) and corresponding floxed control mice. Floxed control mice are shown in open shapes, LysM-Cre-expressing mice are shown in closed shapes. **l,** Western blot analysis of p62, LC3 and actin in *ex vivo* peritoneal MΦ from uninfected mice. **m,** Fold change in *Atg16L1* transcript from *Atg16L1^HM1^* lungs as compared to C57Bl/6 at 3 wpi. **n,** Weight change and **o, p,** log pulmonary CFU of *Atg16L1^HM1^* (open circles) and C57Bl/6 mice (open squares). When used, center values represent the mean ± SEM. Statistical differences were determined by log-rank Mantel-Cox test (**b**), Student's t-test (**d, m,** and **p**) or one-way ANOVA and Bonferonni's multiple comparison test (**h, k**). \* P \< 0.05, \*\* P \< 0.01, \*\*\*\*P \< 0.0001. Notable comparisons that were not significantly different are designated as n.s. Samples represent biological replicates. See [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} for gel source data, [Supplementary Fig. 2](#SD2){ref-type="supplementary-material"} for sample sizes and results from all statistical comparisons.](nihms738923f1){#F1}

![Loss of *Atg5* in LysM^+^ cells leads to earlier and more severe lung inflammation during *Mtb* infection\
**a,** H&E stained histology of lungs at 2 and 3 wpi and gross pathology of lungs at 3 wpi. **b -- d,** C57Bl/6 (grey solid bars), *Atg5^fl/fl^* (blue striped bars), *Atg5^fl/fl^-LysM-Cre* (blue solid bars), *Atg16L1^fl/fl^* (green striped bars), *Atg16L1^fl/fl^-LysM-Cre* (green solid bars). **b,** Concentration of cytokines in lungs (homogenized in 5mL) at 2 and 3 wpi as detected by ELISA. **c, d,** Frequency of alveolar MΦ, PMN, recruited MΦ, and inflammatory monocytes as a percentage of all single cells in lungs at 2 wpi (**c**) and 3 wpi (**d**). Statistical differences were determined by one-way ANOVA and Bonferonni's multiple comparison test (**b--d**). *\* P* \< 0.05, \*\* *P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. Notable comparisons that were not significantly different are designated as n.s. Samples represent biological replicates. See [Supplementary Figure 2](#SD2){ref-type="supplementary-material"} for sample sizes and results from all statistical comparisons, [Extended Data Fig. 5](#F9){ref-type="fig"} for cytokine levels in uninfected lungs, and [Extended Data Fig. 6](#F10){ref-type="fig"} for gating strategy and number of cells in lungs.](nihms738923f2){#F2}

![Depletion of PMN allows for survival of *Atg5^fl/fl^-LysM-Cre* mice during *Mtb* infection\
**a,** Weight change and **b,** survival of *Atg5^fl/fl^-LysM-Cre* mice that received PMN-depleting anti-Ly6G (1A8, closed blue circle), isotype control (IgG, open blue circle), or no treatment (open pink triangle) every other day from 10 -- 28 dpi. **c, d,** *Atg5^fl/fl^* (blue striped bars) and *Atg5^fl/fl^-LysM-Cre* (blue solid bars) mice were treated with IgG or 1A8 and analyzed at 3 wpi. **c,** Cytokine concentration in lungs (homogenized in 5mL) and **d,** log pulmonary CFU. **e,** Pulmonary pathology of *Atg5^fl/fl^-LysM-Cre* mice at 3 wpi following treatment with IgG or 1A8. Statistical differences were determined by one-way ANOVA and Bonferonni's multiple comparison test (**c, d**). *\* P* \< 0.05, \*\* *P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. Notable comparisons that were not significantly different are designated as n.s. Samples represent biological replicates. See [Supplementary Figure 2](#SD2){ref-type="supplementary-material"} for sample sizes and results from all statistical comparisons.](nihms738923f3){#F3}

![Loss of *Atg5* in PMN, but not alveolar MΦ or DCs, can cause susceptibility to *Mtb*\
**a**, Weight change and **b, c,** log pulmonary CFU of *Atg5^fl/fl^* (open circles) and *Atg5^fl/fl^-CD11c-Cre* (closed circles). **d,** Western blot analysis of p62, LC3, and actin in bronchoalveolar MΦ from *Atg5^fl/fl^* and *Atg5^fl/fl^*-*CD11c-Cre* mice. **e,** Western blot analysis of p62, LC3, and actin in bone marrow PMN from *Atg5^fl/fl^, Atg5^fl/fl^*-*LysM-Cre* and *Atg5^fl/fl^*-*MRP8-Cre* mice. **f,** Weight change of *Atg5^fl/fl^* (open blue circles), *Atg5^fl/fl^-LysM-Cre* (closed blue circles), *Atg5^fl/fl^-MRP8-Cre* (closed black diamonds) mice following infection with *Mtb*. **g,** Weight change of mice following infection with *Mtb*. 50% of *Atg5^fl/fl^-MRP8-Cre* mice lost over 5% of their weight by 20 dpi ("susceptible," closed purple triangles) while 50% of *Atg5^fl/fl^-MRP8-Cre* mice did not ("healthy," open black triangles). **h**, Log pulmonary CFU at 3 wpi. **i, j,** C57Bl/6 (grey solid bars), *Atg5^fl/fl^* (blue striped bars), *Atg5^fl/fl^-LysM-Cre* (blue solid bars), "healthy" *Atg5^fl/fl^-MRP8-Cre* (purple striped bars), and "susceptible" *Atg5^fl/fl^-MRP8-Cre* (purple solid bars). **i,** Concentration of cytokines in lungs (homogenized in 5mL) at 3 wpi. **j,** Frequency of alveolar MΦ, PMN, recruited MΦ, and inflammatory monocytes as a percentage of single cells in lungs at 3 wpi. When used, center values represent the mean ± SEM. Statistical differences were determined by one-way ANOVA and Bonferonni's multiple comparison test (**h--j**). *\* P* \< 0.05, \*\* *P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. Notable comparisons that were not significantly different are designated as n.s. Samples represent biological replicates. See [Supplementary Figure 2](#SD2){ref-type="supplementary-material"} for sample sizes and results from all statistical comparisons, and [Extended Data Fig. 7](#F11){ref-type="fig"} for total numbers of cells in lungs.](nihms738923f4){#F4}
